The polypill consisted of three medications: a statin to reduce cholesterol, an ACE inhibitor to lower blood pressure, and aspirin to reduce blood clots.
The study, published in The New England Journal of Medicine, followed almost 2,500 people split into polypill users and traditional medication users.
Researchers plan to submit the study for FDA approval. It’s not the first time the FDA has met to discuss polypills; however, none have been approved yet, according to NBC News. The pill used in this study was approved in Europe in 2014.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
